June 10th 2025
During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with blastic plasmacytoid dendritic cell neoplasm.
Different Approaches Available for Identifying and Managing Chronic GVHD
January 22nd 2024In the first article of a 2-part series, Lori Muffly, MD, MS, discusses with a panel of physicians what their approach is to identifying patients with severe chronic graft-versus-host-disease and how they treat them in conjunction with the transplant team.
Read More
MANIFEST-2: Pelabresib plus Ruxolitinib in JAK Inhibitor–Naïve Myelofibrosis
January 17th 2024Uma Borate, MBBS, and the Oncology Brothers provide insights gleaned from the MANIFEST-2 study, a phase 3, randomized, double-blind study on pelabresib plus ruxolitinib for JAK inhibitor treatment–naïve patients with myelofibrosis.
Watch
TRANSFORM-1: Navitoclax and Ruxolitinib in Untreated Myelofibrosis
January 17th 2024Following ASH 2023, Uma Borate, MBBS, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the TRANSFORM-1 trial investigating navitoclax plus ruxolitinib in patients with untreated myelofibrosis.
Watch